Skip to Main Content
Contribute Try STAT+ Today

Regulators in the U.S. and Europe are investigating why traces of a possible carcinogen were found in certain heartburn drugs, including Zantac, more than a year after the same impurity was found in some blood pressure pills, a revelation that has raised questions about the safety of the pharmaceutical supply chain.

At issue is NDMA, an organic chemical that was once used to make rocket fuel and is an unintended by-product of certain chemical reactions. Last year, the substance was detected in a class of medicines known as angiotensin II receptor blockers, notably, valsartan, prompting an increasing spate of product recalls even as regulators have attempted to reassure consumers that cancer risks are low.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I have been taking large quantities of Zantac over the last year (as prescribed by my physician). Is there a specific cancer risk, like say colon cancer? Or is it more general?

  • All that i will say on this and other health issues with regards to The .F.D.A . and other Federal Health Care Regulatory Institutions . I have no confidence ,nor trust with them . Too much have taken place over time to trust them all .Once again ,Merck years ago is only one of where The F.D.A failed completely resulting in The Deaths of more than five hundred thousands deaths from Vioxx depending on which News Organization you read . i thank you . Trevor . A. Merchant . today . Tuesday . September, 17. 2019 at 4.51 p.m daylight savings time . New York City ,

    • The 500,000 Vioxx deaths stat is fake, sees this Science magazine piece.

      Deaths of this magnitude show up in overall mortality rates – a la the opioid crisis which has resulted in a noticeable bump in mortality. There was no such bump in heart attack deaths during the years Vioxx was prescribed; in fact, heart attack deaths continued to decline.

      There were about four million Vioxx users. In order for that 500K stat to be correct, the drug would have had to kill one in every nine patients!

  • This is an important issue that has to be considered for all drugs.
    Since this impurity was also reported for some antihypertensive drugs, it may come from the inactive ingredients (such as fillers, bonding chemicals etc) that are a part of the pharmaceutical forms such as tablets or capsules.In this case this carcinogen chemical can be avoided by changing the formulation of the pills. On the other hand, from this report it is not clear whether NDMA is formed during the synthesis of ranitidin (or the antihypertensive drug) and thus contamination comes as a byproduct of drug synthesis. In this case source of the active ingradient should be questioned.

  • I’ve taken Zantac for many, many years to protect my stomach from another medicine I have to take that is very hard on the stomach. Can I stop it cold turkey? Is their an equivalent to Zantac that is known not to have this carcinogenic chemical in it?

  • Ed, thanks for reply. Yes patients should get MDs advice on whether to switch meds, but the worry is that the new med may have quality issues as well, but not yet discovered. The other option is to take the brand name vs. generic product, but at the moment, Diovan is 11 times the cost of generic valsartan and if you are within deductible, that comes out of pocket.

Comments are closed.